Rahul D. Ballal Sells 53,400 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Rahul D. Ballal sold 53,400 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $23.95, for a total transaction of $1,278,930.00. Following the completion of the transaction, the director now directly owns 22,341 shares in the company, valued at approximately $535,066.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock traded down $2.74 during trading on Friday, reaching $21.08. The company’s stock had a trading volume of 853,422 shares, compared to its average volume of 210,599. The business’s fifty day moving average price is $16.66 and its 200-day moving average price is $14.16. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $26.00. The firm has a market cap of $868.50 million, a price-to-earnings ratio of -9.73 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.09. Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -2.14 EPS for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently bought and sold shares of ELVN. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics in the 3rd quarter worth $157,000. China Universal Asset Management Co. Ltd. acquired a new stake in Enliven Therapeutics during the fourth quarter worth about $66,000. Exchange Traded Concepts LLC grew its position in Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after buying an additional 2,208 shares in the last quarter. Bank of America Corp DE bought a new position in Enliven Therapeutics during the first quarter valued at about $143,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Enliven Therapeutics in the 4th quarter valued at approximately $140,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Mizuho initiated coverage on shares of Enliven Therapeutics in a report on Tuesday. They issued a “buy” rating and a $34.00 target price on the stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.